BRIEF-Greenwich Lifesciences Provides Clinical Updates On FLAMINGO-01

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSI

0.00

July 20 (Reuters) - Greenwich Lifesciences Inc GLSI.O:

  • GREENWICH LIFESCIENCES PROVIDES CLINICAL UPDATES ON FLAMINGO-01

  • GREENWICH LIFESCIENCES - FLAMINGO-01 DSMB RECOMMENDS STUDY CONTINUE WITHOUT MODIFICATION IN MAY 2026

  • GREENWICH LIFESCIENCES - FLAMINGO-01 STEERING COMMITTEE ENDORSES STUDY SIZE INCREASE AND ACCELERATED ENROLLMENT

  • GREENWICH LIFESCIENCES - FLAMINGO-01 PHASE 3 OBJECTIVES MET FOLLOWING FDA AND EMA REVIEW

  • GREENWICH LIFESCIENCES - Q2 2026 BURN RATE EXPECTED AT $2 MILLION; CASH BALANCE $8.90 MILLION AS OF JUNE 30, 2026

Source text: ID:nGNX6DWTPp

Further company coverage: GLSI.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.